Author:
Sun Ming-Xia,Jing Miao,Hua Ying,Wang Jian-Biao,Wang Sheng-Quan,Chen Li-Lan,Ju Liang,Liu Yan-Shan
Abstract
Abstract
Objective
To analyze the clinical phenotype and genetic characteristics of a female proband carrying a novel mutation in the DMD gene with non-random X-chromosome inactivation in a large pedigree with pseudohypertrophic muscular dystrophy.
Methods
Clinical information of the female proband, her monozygotic twin sister, and other family members were collected. Potential pathogenic variants were detected with Multiplex Ligation-dependent Probe Amplification (MLPA) and whole-exome sequencing (WES). Methylation-sensitive restriction enzyme (HhaI) was employed for X-chromosome inactivation analysis.
Results
The proband was a female over 5 years old, displayed clinical manifestations such as elevated creatine kinase (CK) levels and mild calf muscle hypertrophy. Her monozygotic twin sister exhibited normal CK levels and motor ability. Her uncle and cousin had a history of DMD. WES revealed that the proband carried a novel variant in the DMD (OMIM: 300,377) gene: NM_004006.3: c.3051_3053dup; NP_003997.2: p.Tyr1018*. In this pedigree, five out of six female members were carriers of this variant, while the cousin and uncle were hemizygous for this variant. X-chromosome inactivation analysis suggested non-random inactivation in the proband.
Conclusion
The c.3051_3053dup (p.Tyr1018*) variant in the DMD gene is considered to be the pathogenic variant significantly associated with the clinical phenotype of the proband, her cousin, and her uncle within this family. Integrating genetic testing with clinical phenotype assessment can be a valuable tool for physicians in the diagnosis of progressive muscular dystrophies, such as Becker muscular dystrophy (BMD) and Duchenne muscular dystrophy (DMD).
Publisher
Springer Science and Business Media LLC
Reference24 articles.
1. Writing Group For Practice Guidelines, For D, Treatment Of Genetic Diseases Medical Genetics Branch Of Chinese, Medical A, Tan H, Liang D, Wu L. [Clinical practice guidelines for Duchenne muscular dystrophy]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2020;37(3):258–62.
2. Duan D, Goemans N, Takeda S, Mercuri E, Aartsma-Rus A. Duchenne muscular dystrophy. Nat Rev Dis Primers. 2021;7(1):13.
3. Restrepo-Cordoba MA, Wahbi K, Florian AR, Jimenez-Jaimez J, Politano L, Arad M, Climent-Paya V, Garcia-Alvarez A, Hansen RB, Larranaga-Moreira JM, et al. Prevalence and clinical outcomes of dystrophin-associated dilated cardiomyopathy without severe skeletal myopathy. Eur J Heart Fail. 2021;23(8):1276–86.
4. Verhaart IEC, Aartsma-Rus A. Therapeutic developments for Duchenne muscular dystrophy. Nat Rev Neurol. 2019;15(7):373–86.
5. Flanigan KM, von Niederhausern A, Dunn DM, Alder J, Mendell JR, Weiss RB. Rapid direct sequence analysis of the dystrophin gene. Am J Hum Genet. 2003;72(4):931–9.